|1.||Fava, Maurizio: 15 articles (08/2014 - 09/2002)|
|2.||Krishen, Alok: 12 articles (08/2010 - 01/2003)|
|3.||Rush, A John: 11 articles (03/2012 - 01/2005)|
|4.||Lerman, Caryn: 11 articles (06/2008 - 05/2004)|
|5.||Papakostas, George I: 10 articles (02/2014 - 03/2003)|
|6.||Ebbert, Jon O: 10 articles (01/2014 - 08/2002)|
|7.||Thase, Michael E: 10 articles (01/2014 - 01/2005)|
|8.||Modell, Jack G: 10 articles (08/2010 - 09/2002)|
|9.||Evins, A Eden: 9 articles (03/2015 - 03/2004)|
|10.||Trivedi, Madhukar H: 9 articles (11/2013 - 03/2006)|
|1.||Tobacco Use Disorder (Nicotine Dependence)
02/01/2004 - "Bupropion SR has been shown to be effective for the treatment of nicotine dependence in adults. "
01/01/2002 - "Bupropion SR has also been found to be a useful treatment of tobacco dependence in various special populations of smokers who often experience difficulty in overcoming tobacco addiction. "
08/01/2015 - "Preclinical studies with bupropion in rodent models of nicotine dependence have generated equivocal findings with regard to translating the clinical efficacy of the antidepressant as a smoking cessation agent. "
01/01/2004 - "The aim of the study was a one year evaluation of the efficacy of bupropion SR supported by an educational program in the treatment of nicotine dependence and analysis of the reasons of relapses. "
01/28/2009 - "Ongoing studies continue to explore the behavioural and pharmacological effects of bupropion in smoking cessation studies and animal models of nicotine dependence. "
|2.||Major Depressive Disorder (Major Depressive Disorders)
07/01/2007 - "In addition, neither CBTD nor bupropion, either alone or in combination, was differentially effective for smokers with single-past-episode major depressive disorder (MDD), recurrent MDD, or elevated depressive symptoms. "
01/01/2007 - "Safety and efficacy of bupropion extended release in treating a community sample of Hispanic and african american adults with major depressive disorder: an open-label study."
08/01/2004 - "This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. "
05/01/2013 - "We investigated 532 tagging single nucleotide polymorphisms (SNPs) in 34 candidate genes for association with remission and response to either bupropion (n=319) or placebo (n=257) in patients with major depressive disorder. "
09/01/2013 - "An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features."
10/01/2008 - "Bupropion sustained release may have psychostimulant-like effects and, therefore, may be beneficial in treating fatigue. "
01/01/2003 - "Bupropion SR demonstrated a significant reduction (p<.01, least square mean change) in symptoms over placebo on 4 domains (cognitive, retardation, fatigue/interest, and anxiety items)."
12/15/2006 - "There was also a greater improvement in fatigue scores among bupropion-treated (p < .0001) and SSRI-treated (p = .0005) than placebo-treated patients as well as a greater improvement in fatigue scores among bupropion-treated than SSRI-treated patients (p = .0078). "
11/01/2010 - "A repeat clinical evaluation conducted after 3 months of bupropion treatment indicated an improvement in fatigue (FSS score of 4) without changes in Beck Depression Inventory, Pittsburgh Sleep Quality Index, or Epworth Sleepiness Scale scores. "
02/01/2014 - "Bupropion treatment at the EU-approved dose of ≤300 mg/day may offer advantages over SSRIs in the resolution of sleepiness and fatigue in remitted MDD patients. "
|4.||Weight Loss (Weight Reduction)
07/01/2002 - "To critically examine the efficacy of bupropion SR for weight loss. "
04/01/2013 - "The preliminary findings regarding short-term weight losses suggest the need for larger and longer-term trials to evaluate the potential utility of bupropion for enhancing outcomes of psychological interventions that have demonstrated effectiveness for BED but fail to produce weight loss. "
04/01/2007 - "Although originally developed as an antidepressant, long-term bupropion (BUP) treatment was recently shown to cause 5-8% weight loss over placebo in clinical trials with obese adults. "
07/01/2002 - "Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial."
09/01/2001 - "Subjects receiving bupropion achieved greater mean weight loss (last-observation-carried-forward analysis) over the first 8 weeks of the study (p = 0.0001): 4.9% +/- 3.4% (n = 25) for bupropion treatment compared with 1.3% +/- 2.4% (n = 25) for placebo treatment. "
|5.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
07/01/2007 - "Since attention-deficit/hyperactivity disorder (ADHD) is a well-documented risk factor for smoking and bupropion has been shown to be effective for smoking cessation, we tested the efficacy of bupropion as a prophylactic agent for the prevention of smoking in children and adolescents with ADHD. "
10/01/1996 - "This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). "
12/01/2011 - "Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials."
04/01/2005 - "Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study."
08/01/1990 - "The authors treated 19 adults with attention-deficit hyperactivity disorder with an open trial of bupropion. "
|4.||Antidepressive Agents (Antidepressants)
|1.||Drug Therapy (Chemotherapy)
|4.||Nebulizers and Vaporizers (Inhaler)